Aktienanalyse zu Chronoscale Corp (CHRN)CHRNChronoscale Corp

ChronoScale Corporation, formerly Ekso Bionics Holdings, Inc., designs, develops, and markets exoskeleton products. Its exoskeleton technology serves people with physical disabilities or impairments in both physical rehabilitation and mobility. The Company operates as one segment with two markets: Enterprise Health and Personal Health. Its products include EksoNR, which is a wearable robotic exoskeleton designed for a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower limb-powered exoskeleton; Ekso Indego Personal is a lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. It enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate, stand and walk again. It assists people to perform challenging repetitive tasks for extended periods. It operates in the Healthcare sector.

Currently, Ekso Bionics Holdings, Inc. (CHRN) is not a good buy. The stock is trading at $15.08, which is significantly below its analyst price target of $32, indicating potential upside. However, the RSI is at a low 26.447, suggesting it is oversold but also reflects weak momentum. The company has reported a staggering 18.88% decline over the past five days and a 26.15% drop over the last 20 days, indicating a bearish trend. The main risk is its net income, which has been consistently negative, with a recent report showing a loss of $42,484,000 in Q3 2026, raising concerns about its financial stability.